Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2019-05-15 Capital/Financing Update
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of common stock by ADMA Biologics, Inc. It is filed pursuant to Rule 424(b)(5) under the Securities Act, which is a form used for prospectus supplements in registered securities offerings. The text includes detailed information about the offering, underwriting, risk factors, use of proceeds, and legal matters, typical of a capital raising document. There is no financial statement data or earnings information, nor is it an annual or quarterly report. It is clearly a document related to capital raising and financing activities, specifically a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual prospectus supplement, not just an announcement of a report, so it is not RPA or RNS. Confidence is high given the explicit nature of the document and its regulatory filing type.
2019-05-15 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 15, 2019. It updates prior disclosures made in the company's Annual Report on Form 10-K for the year ended December 31, 2018. The content includes detailed business updates about the plasma industry, primary immunodeficiency disease, immune globulins, and intellectual property. There is no presentation of full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a regulatory filing to update investors and the SEC on material business developments and intellectual property status. The document is lengthy (15,000 characters) and contains substantive information but is not a full financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2019-05-15 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text indicates it announces FDA approval of a supplement for a product and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document length is only 3395 characters, which is relatively short. It is an announcement of an event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-05-10 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-08 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2019, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2019. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document itself does not contain the financial results but announces their release. The length is 3502 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing the release of financial results without containing the actual financial data should be classified as a Regulatory Filing (RNS), as it does not contain the full earnings release or detailed financial statements but is a current report announcing the event.
2019-05-08 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the company's entry into a material definitive agreement related to a credit facility amendment, including drawdowns of term loans, issuance of a warrant, and related financial obligations. It includes detailed terms of the credit agreement amendment and related financial instruments. This is a financing update rather than a full financial report or earnings release. The document is not an annual or interim report, nor is it a transcript, proxy, or governance document. It fits the category of Capital/Financing Update (CAP) as it provides updates on the company's financing activities and capital structure changes.
2019-05-03 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.